Bladder cancer, one of the most prevalent malignant
cancers, has high rate of recurrence and
metastasis. Owing to
genomic instability and high-level heterogeneity of
bladder cancer,
chemotherapy and
immunotherapy drugs sensitivity and lack of prognostic markers, the prognosis of
bladder cancer is unclear. Necroptosis is a programmed modality of necrotic cell death in a
caspase-independent form. Despite the fact that necroptosis plays a critical role in
tumor growth,
cancer metastasis, and
cancer patient prognosis, necroptosis-related gene sets have rarely been studied in
bladder cancer. As a result, the development of new necroptosis-related prognostic indicators for
bladder cancer patients is critical. Herein, we assessed the necroptosis landscape of
bladder cancer patients from The
Cancer Genome Atlas database and classified them into two unique necroptosis-related patterns, using the consensus clustering. Then, using five prognosis-related genes, we constructed a prognostic model (risk score), which contained 5 genes (ANXA1, DOK7, FKBP10,
MAP1B and SPOCD1). And a nomogram model was also developed to offer the clinic with a more useful prognostic
indicator. We found that risk score was significantly associated with clinicopathological characteristics, TIME, and
tumor mutation burden in patients with
bladder cancer. Moreover, risk score was a valid guide for
immunotherapy,
chemotherapy, and targeted drugs. In our study, DOK7 was chosen to further verify our prognosis model, and functional assays indicated that knockdown the expression of DOK7 could prompt
bladder cancer proliferation and migration. Our work demonstrated the potential role of prognostic model based on necroptosis genes in the prognosis, immune landscape and response efficacy of
immunotherapy of
bladder cancer.